Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- David Garcia Cinca
- Target Recruit Count
- 160
- Registration Number
- NCT02643212
- Locations
- 🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Complejo Hospitalario de Pontevedra_Hospital Montecelo, Pontevedra, Spain
🇪🇸Hospital German Trias i Pujol, Badalona, Barcelona, Spain
Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Japan Cardiovascular Research Foundation
- Target Recruit Count
- 2200
- Registration Number
- NCT02642419
- Locations
- 🇯🇵
Japan Cardiovascular Research Foundation, Suita, Osaka, Japan
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 321501
- Registration Number
- NCT02640222
Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Università degli Studi dell'Insubria
- Target Recruit Count
- 100
- Registration Number
- NCT02627053
- Locations
- 🇨🇦
University of Western Ontario, London, Canada
🇨🇦University of Ottawa, Ottawa, Canada
🇮🇹Ospedale di Circolo, Varese, Italy
Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Onze Lieve Vrouw Hospital
- Target Recruit Count
- 117
- Registration Number
- NCT02610933
- Locations
- 🇧🇪
OLV Hospital, Aalst, Belgium
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 246
- Registration Number
- NCT02583191
- Locations
- 🇩🇪
Uniklinik, Aachen, Germany
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 114
- Registration Number
- NCT02584660
A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 158
- Registration Number
- NCT02561923
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 72
- Registration Number
- NCT02559856
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 841
- Registration Number
- NCT02555878
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.